NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

香港腳(足癬)治療的全球市場

Tinea Pedis (Athlete's Foot) Treatment

出版商 Global Industry Analysts, Inc. 商品編碼 997873
出版日期 內容資訊 英文 274 Pages
商品交期: 最快1-2個工作天內
價格
香港腳(足癬)治療的全球市場 Tinea Pedis (Athlete's Foot) Treatment
出版日期: 2021年04月01日內容資訊: 英文 274 Pages
簡介

全球香港腳(足癬)治療的市場規模,預計在分析期間(2020年∼2027年)將以1.8%的年複合成長率增長,從2020年的9億3,330萬美元,到2027年達到11億美元。

本報告所分析的市場區隔之一的口服部門,分析期間中預計將以2.3%的年複合成長率增長,達到4億5,660萬美元。

本報告提供全球香港腳(足癬)治療市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Alva-Amco Pharmacal Companies, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • ProFoot, Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Taisho Pharmaceutical Co., Ltd.
  • Taro Pharmaceutical Industries Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:43公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6540

Abstract:

Global Tinea Pedis (Athlete's Foot) Treatment Market to Reach $1.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Tinea Pedis (Athlete's Foot) Treatment estimated at US$933.3 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at aCAGR of 1.8% over the period 2020-2027. Oral, one of the segments analyzed in the report, is projected to record 2.3% CAGR and reach US$456.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Topical segment is readjusted to a revised 1.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $252.7 Million, While China is Forecast to Grow at 3.5% CAGR

The Tinea Pedis (Athlete's Foot) Treatment market in the U.S. is estimated at US$252.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$203.8 Million by the year 2027 trailing a CAGR of 3.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.2% and 1.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.6% CAGR.

Select Competitors (Total 43 Featured) -

  • Alva-Amco Pharmacal Companies, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • ProFoot, Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Taisho Pharmaceutical Co., Ltd.
  • Taro Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Interdigital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Interdigital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Interdigital by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Vesicular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Vesicular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Vesicular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 16: USA Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 17: USA Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: USA 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 19: USA Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 22: Canada Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Canada Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: Canada 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 25: Canada Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 28: Japan Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Japan Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Japan 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 31: Japan Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 34: China Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: China Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: China 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 37: China Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 40: Europe Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Europe 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 43: Europe Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 46: Europe Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 49: France Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: France Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: France 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 52: France Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: France Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: France 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 55: Germany Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Germany Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Germany 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 58: Germany Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Germany Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Germany 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 61: Italy Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Italy Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Italy 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 64: Italy Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Italy Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Italy 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 67: UK Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: UK Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: UK 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 70: UK Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: UK Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: UK 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 73: Spain Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Spain Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Spain 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 76: Spain Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Spain Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Spain 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 79: Russia Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Russia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Russia 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 82: Russia Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Russia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Russia 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 85: Rest of Europe Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Europe 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 88: Rest of Europe Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of Europe 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 91: Asia-Pacific Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 92: Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Asia-Pacific 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 94: Asia-Pacific Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Asia-Pacific 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 97: Asia-Pacific Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 100: Australia Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Australia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Australia 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 103: Australia Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Australia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Australia 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 106: India Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: India Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: India 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 109: India Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: India Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: India 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 112: South Korea Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: South Korea Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: South Korea 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 115: South Korea Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: South Korea Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: South Korea 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 118: Rest of Asia-Pacific Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Rest of Asia-Pacific 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 121: Rest of Asia-Pacific Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Rest of Asia-Pacific 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 124: Latin America Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 125: Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Latin America 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 127: Latin America Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Latin America 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 130: Latin America Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Latin America 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 133: Argentina Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Argentina Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Argentina 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 136: Argentina Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Argentina Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Argentina 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 139: Brazil Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Brazil Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Brazil 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 142: Brazil Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Brazil Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Brazil 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 145: Mexico Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Mexico Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Mexico 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 148: Mexico Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Mexico Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Mexico 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 151: Rest of Latin America Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Rest of Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Rest of Latin America 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 154: Rest of Latin America Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Rest of Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Rest of Latin America 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 157: Middle East Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 158: Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Middle East 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 160: Middle East Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Middle East 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 163: Middle East Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Middle East 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 166: Iran Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Iran Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Iran 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 169: Iran Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Iran Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Iran 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 172: Israel Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Israel Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Israel 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 175: Israel Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Israel Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Israel 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 178: Saudi Arabia Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Saudi Arabia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Saudi Arabia 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 181: Saudi Arabia Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Saudi Arabia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Saudi Arabia 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 184: UAE Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: UAE Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: UAE 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 187: UAE Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: UAE Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: UAE 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 190: Rest of Middle East Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Middle East 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 193: Rest of Middle East Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Middle East 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 196: Africa Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Africa Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Africa 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
    • TABLE 199: Africa Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Africa Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Interdigital and Vesicular Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Africa 15-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease Type - Percentage Breakdown of Value Sales for Interdigital and Vesicular for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 43